ResMed (RMD) witnessed a 4% rise post its last earnings report. The company is considered a strong growth and momentum stock, with a 52% profit jump and record margins in one quarter. The company's Q3 earnings and revenues surpassed estimates. However, there are concerns over its debt usage and sale of shares by insiders, with instances of Witte De and Peter Farrell selling 2,000 units of ResMed Inc's stock.
Resmed recently acquired VirtuOx and partnered with a rugby tour to promote sleep health. It had an 80-plus relative strength rating after rising 80% in a year. Despite the better-than-expected sales in Q4, the stock dropped. There have been economic concerns leading to adjustments in price targets. Nevertheless, Revenue in Q1 was in line with expectations and Citigroup upgraded ResMed.
Resmed faces potential market challenges from new sleep apnea treatments and organic sales growth has stepped down. The company's 2025 Q3 results indicate strong revenue growth and strategic advancements. The company recently revealed its 2030 Strategy for growth, profitability, and shareholder returns.
Resmed RMD News Analytics from Tue, 27 Aug 2024 07:00:00 GMT to Fri, 23 May 2025 15:30:57 GMT - Rating 7 - Innovation 4 - Information 9 - Rumor 6
